VLA Vela Minerals Ltd

The vaccine was developed by the Chemo-Sero Therapeutic Research Institute (Kaketsuken) in collaboration with GlaxoSmithKline using Valneva's EB66® cell line, this represents a potential of 80 million vaccine doses to be produced in the event of a pandemic.

To download the full press release, please click on the following icon:

2015_03_26 Valneva CC Prototype Flu Vaccine ENG http://hugin.info/143334/R/1906344/678670.pdf 2015_03_26 Valneva CC Prototype Flu Vaccine FRA http://hugin.info/143334/R/1906344/678672.pdf 2015_03_26 Valneva CC Prototype Flu Vaccine GER http://hugin.info/143334/R/1906344/678673.pdf

HUG#1906344

CONTACT: Florence Hocdee- Leroy
         T: +33 (0)228 07 37 10
         M: +33 642 04 42 14
         
         Teresa Pinzolits
         T: +43-1-206 20-1116
         M: +43 676 845567357
         
         Communications@valneva.com